INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IN8BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.09−0.02 (-1.80%)
Close on Oct 19, 2026
- Market cap
- $21.22M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.98 (−47.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $21.22M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.16
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$18.67M
- EPS, diluted
- -$2.06
- Book value per share
- $0.94
- Diluted shares
- 19M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$18.67M
Net income
-$18.67M
EPS, diluted
-$2.06
Reported periodTrailing twelve months